Why do brain-dead organ donors develop hyperglycemia?

Why Brain-Dead Donors Develop Hyperglycemia

Brain-dead organ donors develop hyperglycemia primarily due to a massive stress response that causes peripheral insulin resistance, increased endogenous glucose production, and impaired glucose clearance—not from beta-cell failure, though recent evidence suggests beta-cell death may also contribute in donors requiring insulin therapy.

Primary Mechanisms

The hyperglycemia in brain-dead donors results from multiple overlapping pathophysiological processes:

Stress-Induced Insulin Resistance

The dominant mechanism is peripheral insulin resistance 1. Brain death triggers an extreme physiological stress state characterized by:

• Massive catecholamine surge during the sympathetic storm accompanying brain herniation
• Elevated stress hormones (glucagon, cortisol, catecholamines) 1
• Inflammatory mediators (interleukin-1, interleukin-6) that directly impair insulin signaling 1
• Increased free fatty acid release that further aggravates insulin resistance 1

Enhanced Glucose Production

Beyond insulin resistance, brain death stimulates:

• Increased hepatic gluconeogenesis 1
• Enhanced glycogenolysis 2
• Increased renal glucose reabsorption 1
• Decreased peripheral glucose clearance 1

Beta-Cell Dysfunction and Death

Contrary to traditional teaching that pancreatic function remains intact, recent high-quality evidence demonstrates that beta-cell death occurs in brain-dead donors 3. In donors requiring insulin therapy:

• Significantly elevated markers of beta-cell death (unmethylated insulin gene promoter cell-free DNA and microRNA-375) 3
• Poorer glycemic control despite elevated C-peptide levels 3
• This beta-cell death strongly predicts post-transplant graft dysfunction 3

However, earlier studies showed that most donors maintain effective endocrine pancreatic function with elevated insulin and C-peptide levels, suggesting the primary issue is insulin resistance rather than absolute insulin deficiency 4.

Clinical Context and Prevalence

Hyperglycemia develops in 79.2% of brain-dead donors 5, with severity varying based on:

• Duration of brain death - longer intervals worsen metabolic derangements 4
• Catecholamine infusion requirements 1
• Corticosteroid use 1
• Underlying trauma severity 1
• Development of diabetes insipidus (occurs in 70.8% of cases) 5, which complicates fluid management

Pathophysiological Consequences

The hyperglycemia itself causes additional organ damage through:

• Endothelial dysfunction 1
• Impaired phagocytic activity of neutrophils 1
• Abolished ischemic preconditioning 1
• Increased blood-brain barrier damage 1
• Worsening terminal renal function - higher glucose levels directly correlate with elevated terminal creatinine and delayed graft function in kidney recipients 6

Management Implications

Aggressive glucose control is critical because:

• Poor glucose homeostasis associates with worsening donor organ function, particularly renal function 6
• High-dose insulin therapy (hyperinsulinemic-normoglycemic clamp) not only controls glucose but also suppresses the inflammatory response 7, decreasing pro-inflammatory cytokines (IL-6, MCP-1) and increasing anti-inflammatory cytokines (IL-10)
• Quality improvement projects targeting glucose control (maintaining mean glucose 162 mg/dL vs 212 mg/dL) significantly preserve terminal renal function 6

Common Pitfalls

• Assuming hyperglycemia reflects only insulin resistance: Recent evidence shows actual beta-cell death occurs, particularly in donors requiring insulin 3
• Undertreating hyperglycemia: The stress response is so severe that standard insulin dosing is often inadequate 7
• Ignoring the inflammatory component: Insulin therapy provides anti-inflammatory benefits beyond glucose control 7
• Failing to recognize diabetes insipidus: This develops in 70.8% of cases and complicates glucose management through massive fluid shifts 5

The hyperglycemia represents a complex interplay of extreme physiological stress, insulin resistance, enhanced glucose production, and in some cases, actual beta-cell death—all of which require aggressive management to optimize donor organ quality and recipient outcomes.